Company ProfilePremium

Bio-Gene Technology Limited

Company Profile Analysis

Ticker: BGT.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Bio-Gene Technology Limited - Company showcase

Year Founded & Workforce

1995

1 Employees

Bio-Gene Technology Limited logo

Bio-Gene Technology Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Bio-Gene Technology Limited Overview

Bio-Gene Technology is a pre-revenue Australian agtech developer that owns two insecticidal active ingredients based on beta-triketone chemistry found in a sub-type of Eucalyptus. Flavocide (flavesone) is a synthesised, nature-identical molecule. Qcide is a steam-distilled eucalyptus oil rich in tasmanone. The company's core claim is a novel mode of action. That matters because insecticide resistance is eroding the established chemical classes in public health mosquito control, crop protection, grain storage, animal health and consumer pest control. Bio-Gene runs an asset-light, out-licensing model. It aims to own the active-ingredient registrations and manufacturing know-how, while partners (Envu, Clarke, Evergreen Garden Care, STK, and Sumitomo/Nakashima in Japan) formulate, register end products and sell. At about A$6M market capitalisation, with A$1.94M of cash at FY2026 year end and a going-concern material uncertainty, the investment case is binary. It rests on Flavocide clearing GLP toxicology and an Australian (APVMA) filing in Q2 CY2027, and on Qcide generating first commercial revenue in Japan.


Company's own description (paraphrased from FY2026 AR, "Who We Are" and Principal Activities). Bio-Gene describes itself as an Australian agtech development company. Its stated goal is to enable a new generation of insecticides that address food security and public health while dealing with insecticide resistance and toxicity. The technology rests on naturally occurring beta-triketone compounds, with applications in crop protection (including grain storage), public health, consumer and animal health. The company cites estimates that around 600 insect and arthropod types resist more than one insecticide class, and that more than 60 countries report mosquito resistance. It sizes the global insecticide market at over US$31 billion per year.

Business model (FY2026 AR). The model has four parts:

  1. Develop and own active-ingredient registrations internationally, starting with an APVMA application for Flavocide as a new active constituent.

  2. Develop proprietary manufacturing and production know-how. Flavocide synthesis was scaled at pilot level with Rallis India. Qcide oil comes from Bio-Gene's own Queensland plantation and distillation process.

  3. Partner with established companies for formulation, product registration, marketing and distribution.

  4. Earn revenue from active-ingredient supply, technology licence fees, milestone payments and royalties.

Revenue model mix (as of FY2026).

Value-chain position. Bio-Gene sits upstream, at active-ingredient discovery, development and registration. This is the same position as agrochemical majors' discovery units, but without their capital base. Manufacturing is outsourced: Flavocide toll synthesis in India, and Qcide biomass grown on a leased or managed Queensland plantation with distillation. Toxicology work goes to overseas GLP contract research organisations. Formulation and end-product commercialisation are delegated to partners.

Customer types (prospective). Professional pest management and mosquito-abatement companies (Envu, Clarke). Consumer home-and-garden brands (Evergreen Garden Care; Nakashima Trading in Japan). Crop-protection companies (STK Bio-Ag for Qcide in crop protection; earlier BASF for grain storage). Government and defence programmes (US Department of Defense Deployed Warfighter Protection; US CDC vector-control programme). Trading houses (Sumitomo Corporation).

End-markets. Public health vector control (mosquitoes, ticks). Consumer and household pest control. Professional pest management. Crop protection and organic agriculture (Qcide has OMRI listing). Grain storage. Animal health.

Independent characterisation. Bio-Gene is a micro-cap, single-segment, pre-commercial R&D company. Its economics resemble a pre-clinical biotech more than an agrochemical business. Over FY2022–FY2026 its cumulative operating cash burn was about A$12.5M, funded almost entirely by equity and the R&D tax incentive. Its main asset is a patent family around flavesone and tasmanone uses and synergies, plus one plantation-based supply chain for Qcide. The FY2026 annual report marks the shift from "discovery and evaluation" to "regulatory dossier and first commercial term sheet". Nothing is yet binding or revenue-generating.

Strategy

Stated strategy (FY2026 AR, paraphrased). Bio-Gene's strategy is to develop its proprietary technologies until they can be licensed to commercial partners for further development and market release. It would then earn revenue from active-ingredient supply, milestones and royalties. Recurring themes in the Chair and CEO letter are:

  1. a novel mode of action as the differentiator against resistance;

  2. nature-derived safety and sustainability positioning;

  3. owning the active-ingredient registration;

  4. partnering for formulation and distribution;

  5. building scalable, low-cost supply.

Strategic initiatives, last 24 months (Oct 2024 – Oct 2026).

Cost programmes. No formal cost-reduction target has been announced. The asset-light outsourcing policy is the main cost discipline: no material capex is intended in the near term (FY2026 AR).

ESG commitments. None quantified. The company says its operations are not subject to significant environmental regulation.

Medium-term guidance. No financial guidance is provided. The AR says further disclosure on likely developments would unreasonably prejudice the company. The operational milestones guided for FY2027 are: Flavocide toxicity results; APVMA submission (Q2 CY2027); Asian mosquito results (Q4 CY2026); and Qcide Japan launch (late CY2026).

Products & Services

Bio-Gene has no products on sale. Its portfolio consists of two active ingredients and their targeted use patterns, often called "products" in company materials. The FY2026 annual pipeline review kept eight priority target products and use patterns. The company has not published the full list of eight, so the catalogue below is assembled from disclosed programmes.

Flavocide® (active constituent: flavesone)

AttributeDetail
DescriptionSynthetically produced, nature-identical beta-triketone (flavesone) originally found in eucalyptus leaf biomass
Key capabilityNovel mode of action, different from all currently available insecticides per company research. Efficacy shown against resistant pest populations. Synergy with pyrethroids (permethrin, pyrethrin).
ManufacturingProprietary synthesis route owned by Bio-Gene. Pilot-scale production by Rallis India (Dahej) produced several hundred kg at consistent specification (Sep 2024).
Regulatory statusAPVMA pre-application assistance done. GLP dossier under construction: OECD 407 (28-day) done; OECD 417 pilot done; OECD 424 and 443 in progress (preliminary reports were expected Sep 2026); OECD 408 (90-day), OECD 417 GLP and OECD 414 (rabbit developmental) still to come; 5-batch analysis and storage stability underway. First APVMA application targeted Q2 CY2027. Intended label scope: professional and domestic uses including public health mosquito control, excluding food production at first.
Target customersProfessional mosquito control (Envu, Clarke), consumer (Evergreen Garden Care), defence (US DoD), animal health, grain storage (historical BASF work)
Pricing modelNot publicly disclosed. Intended to combine active-ingredient supply margin, licence fees, milestones and royalties.
Launch yearNone. No registered product as of Oct 2026.
ProgrammeDescriptionPartner(s)Stage (latest disclosure)
Professional mosquito controlFormulations for mosquito management in professional pest-control use patternsEnvu (since Aug 2024)Several formulations evaluated (FY2025 AR); confidential development continuing
Mosquito barrier sprayResidual barrier spray use patternClarke Mosquito Control (US)Formulation optimisation (H1 FY2024)
Wearable mosquito-protection device (spatial emanator)Device releasing Flavocide to protect against flying vectorsUS DoD DWFP grant; GearJump Technologies; US military and agricultural research institutionsPrototypes built; early small-cage trials showed mosquito mortality (FY2026 AR)
Tick control (acaricide)Emulsion-in-water prototype against Ixodes scapularisPurdue University>90% nymph mortality in 24h, up to 4 weeks residual (lab); field validation proposed
Asian vector controlTesting vs Aedes aegypti, Ae. albopictus, Culex quinquefasciatus to WHO guidelinesTesting facilities in Singapore and the region (unnamed)Initial phase completion expected Q4 CY2026
Consumer home & gardenConsumer insecticide applicationsEvergreen Garden CareOngoing (FY2025 AR)
Stored-grain protectionGrain protectant, alone and in combinationsBASF (historical), GRDC, Queensland DAFMet key industry standards in grain-storage trials (historical); current status not disclosed
Synergistic combination productsFlavesone + permethrin or pyrethrinLicensing opportunityUS patent to 2040; equivalents granted in AU, JP, NZ, 22 ARIPO states

Named Flavocide programmes and use patterns

Qcide® (active constituent: tasmanone-rich eucalyptus oil)

AttributeDetail
Description100% natural, non-synthetic oil steam-distilled from leaves of a selected Eucalyptus cloeziana (Gympie Messmate) cultivar, high in tasmanone
Key capabilityNovel mode of action. Ovicidal activity (national-phase patent filings). Botanical and organic positioning.
ProductionOwn plantation in Far North Queensland. 14th harvest Jul 2025 and 15th harvest Feb 2026 at consistent commercial specification. Biomass pre-treatment and distillation being optimised. Tree-improvement programme and seed production area established. New plantings ready for first harvest in spring 2026.
Regulatory / market accessOMRI Listed (Dec 2025) as a botanical pesticide under USDA NOP, with no restrictions on composition. This is not itself a product registration. Japanese import and supply approval application initiated.
Target customersJapanese household nuisance-insect market (Nakashima via Sumitomo); organic agriculture and crop protection (STK); defence and indoor pests (US DoD)
Pricing modelNot publicly disclosed. Japan structure: Bio-Gene supplies oil and licenses IP; Sumitomo handles ordering, trade finance, logistics and import approval; Nakashima formulates, packages and sells.
LaunchTargeted late CY2026 in Japan (non-binding)
ProgrammeDescriptionPartner(s)Stage
Japan household insecticidesRange of products containing Qcide against household nuisance insectsSumitomo Corporation; Nakashima Trading Co. LtdNon-binding term sheet (Mar 2026); draft commercial terms, import approval application, prototype formulations, packaging work
Crop protection (global)Qcide-based biological crop protectionSTK Bio-Ag Technologies (Development & Licence Agreement, Jul 2023)STK funds registration; current milestones not disclosed
Indoor residual treatmentBed bugs, resting houseflies, indoor pestsUS DoD DWFP grant; US research partnersLaboratory testing of prototypes, starting with houseflies
OvicideEgg-stage controlIPNational phase entered: AU, BR, CA, EU, IN, JP, NZ, US
Asian vector controlAs for Flavocide—Results Q4 CY2026

Named Qcide programmes

Services

None.

Financial Narrative

Data bases. FY2025–FY2026 are taken from the audited FY2026 Annual Report. FY2022–FY2024 come from S&P Global Market Intelligence (via StockAnalysis) and are reconciled to the AR where possible. S&P's "revenue" line for FY2022–FY2024 probably captures grant or collaboration income. A second aggregator (Stoxray) reports FY2023 revenue of A$0.595M and FY2024 revenue of A$0.018M, against S&P's A$0.15M and A$0.02M. This discrepancy is flagged. The company's own Appendix 4E reports nil revenue from ordinary activities in FY2025 and FY2026.

Income statement

EPS for FY2022–FY2024 is S&P data rounded to whole cents. FY2024 weighted average shares is approximate (S&P). FY2025–FY2026 are exact per AR Note 4. FY2026 operating loss excludes A$0.025M interest income. The FY2026 gross profit line is not meaningful.

Margins and growth

Gross, operating, EBITDA and net margins are not meaningful for any year from FY2022 to FY2026. Revenue is nil or immaterial: the FY2024 operating loss of A$2.50M sat against A$0.02M of revenue, and S&P reports an FCF margin of minus 15,065%. The 5-year revenue CAGR is not meaningful because revenue fell from A$0.45M (FY2022) to nil (FY2025–FY2026). A more useful measure is net-loss CAGR, FY2022–FY2026, of about −5.5% per year. The loss narrowed from A$2.91M to A$2.33M.

Balance sheet

The FY2025 short-term "debt" is an A$51,209 insurance premium funding liability (AR Note 12). Small loan repayments of A$0.08M appear in FY2022–FY2023 financing cash flows (S&P), but no debt balance is shown. Net tangible assets per share were 0.5 cents in both FY2025 and FY2026 (Appendix 4E). Unrecognised tax losses are A$18.47M, a potential benefit of A$4.62M at 25% (FY2026 AR).

Cash flow

FY2026 operating cash flow benefited from A$0.59M of "other income" receipts (mainly grant cash) and A$0.52M of R&D tax refund, received in Nov 2025 for FY2025 spending (AR cash flow statement).

Ratios

ROIC, interest coverage, net debt/EBITDA, asset turnover and cash conversion cycle are not meaningful. Invested capital is negligible, interest expense is close to zero (A$2,559 in FY2026), EBITDA is negative, and the company holds no inventory or trade receivables.

Commentary

Trend 1: steady but modest losses. Net losses have stayed in a narrow A$2.3–3.1M band for five years, peaking in FY2023 at A$3.10M. FY2026's A$2.33M loss is the lowest in the period. It was not driven by spending cuts: total operating expenses actually rose 9.7% to A$3.41M. The improvement came from other income doubling to A$1.08M, mainly because US DoD research-grant income rose from A$0.10M to A$0.58M (AR Note 3a). In effect, US government money is now meaningfully subsidising the R&D budget.

Trend 2: spending is shifting toward regulatory R&D. R&D expense rose 28% to A$1.77M in FY2026. Within it, consulting jumped from A$0.14M to A$0.54M and studies and development rose to A$0.77M. Commercialisation salaries and management or corporate costs both fell. This mix shift matches the move into GLP toxicology. Another A$625,000 of study fees is committed for OECD 443 and 417 work, payable before the end of FY2027 (AR Note 16). IP costs rose 37% to A$0.34M as patent families entered national phase.

Trend 3: the balance sheet steps down, then is partly refilled. Cash fell from A$6.34M (FY2022) to A$1.14M (FY2025), when runway reached about 0.45 years. That forced the May–July 2025 and May–August 2026 raises. Equity has been rebuilt to A$2.09M, but at a cost. Shares on issue rose 2.4x, from 179M (FY2022) to 438M (Aug 2026), and 179M options remain outstanding. The quarterly report for Q1 FY2026 noted only about 0.98 quarters of funding before new capital arrived (InvestSMART summary, Oct 2025).

Trend 4: going concern. Both the FY2026 annual report and the H1 FY2026 half-year report disclose a material uncertainty about going concern. Directors rely on forecast capital raising and R&D tax refunds. A pro-forma cash figure combining 30 June cash (A$1.94M) and the post-balance-date tranche 2 and SPP shortfall proceeds (A$1.25M gross) is about A$3.19M before costs and before July–September burn. This is arithmetic only, not a disclosed figure. At the FY2026 burn rate, that implies runway into roughly mid-CY2027, which is about the targeted APVMA filing window. Additional capital before or around the filing looks likely.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment and Revenue by Segment (%)

MetricFY2024FY2025FY2026

Segment revenue (AUD Mn, S&P basis)

0.0200

Segment other income incl. R&D TI and grants (AUD Mn)

00.521.08

Segment pre-tax loss (AUD Mn)

-2.41-2.58-2.33

Segment share of total revenue (%)

100100100

Functional cost centre (AUD Mn)

Functional cost centre (AUD Mn)FY2025FY2026

Research & Development

1.381.77

Commercialisation (incl. farm management)

0.560.45

Intellectual Property

0.250.34

Management & Corporate

0.620.49

Directors

0.190.19

Professional services

0.070.13

Depreciation & amortisation

0.040.04

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD Mn, S&P basis)

0.450.150.0200

Gross profit (AUD Mn, S&P basis)

0.22-0.12-0.30-0.250

R&D expense (AUD Mn)

1.901.981.071.381.77

Operating loss (AUD Mn)

-2.97-3.18-2.50-2.62-2.36

EBITDA (AUD Mn, op. loss + D&A)

-2.93-3.13-2.46-2.58-2.32

Pre-tax loss (AUD Mn)

-2.91-3.10-2.41-2.58-2.33

Net loss (AUD Mn)

-2.91-3.10-2.41-2.58-2.33

Basic/diluted EPS (A$ cents)

-2.0-2.0-1.0-1.22-0.75

Dividends per share (A$ cents)

00000

Weighted avg shares (M)

179178190185.82309.11

Income Statement

MetricFY2025FY2026

R&D tax incentive (AUD Mn)

0.390.47

Research grants (AUD Mn)

0.100.58

Interest (AUD Mn)

0.040.02

Other (AUD Mn)

0.000

Total other income (AUD Mn)

0.521.08

Total operating expenses (AUD Mn)

3.113.41

Balance Sheet and Share Count (M)

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD Mn)

7.303.843.162.152.61

Cash & equivalents (AUD Mn)

6.342.992.211.141.94

Short-term debt (AUD Mn)

0000.050

Long-term debt (AUD Mn)

00000

Net debt (AUD Mn, negative = net cash)

-6.34-2.99-2.21-1.09-1.94

Total liabilities (AUD Mn)

1.030.610.370.520.52

Shareholders' equity (AUD Mn)

6.273.222.791.632.09

Goodwill (AUD Mn)

00000

Intangibles – Qcide licences (AUD Mn)

0.280.240.200.170.13

Working capital (AUD Mn)

5.993.012.591.461.96

Accumulated losses (AUD Mn)

-14.50-17.43-19.64-22.03-24.20

Shares on issue at 30 Jun (M)

179.06177.91201.36266.42386.08

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

-1.99-3.28-2.75-2.54-1.94

Capex (AUD Mn, outflow)

0.0100.0100

Free cash flow (AUD Mn)

-2.00-3.28-2.76-2.54-1.94

Equity issued, gross (AUD Mn)

4.7202.031.502.99

Share issue costs (AUD Mn)

0.2400.060.080.20

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

R&D tax incentive cash received (AUD Mn)

0.510.450.500.540.52

Net change in cash (AUD Mn)

2.41-3.35-0.78-1.070.80

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE (%, year-end equity)

-46.4-96.3-86.4-158.3-111.5

ROA (%, year-end assets)

-39.9-80.7-76.3-120.0-89.3

Current ratio (x)

6.936.288.403.864.78

Debt/equity (x)

0000.030

Cash runway at year-end burn (years)

3.190.910.800.451.00

Results by Region

MetricFY2024FY2025FY2026

Australia – R&D tax incentive income (AUD Mn)

00.390.47

United States – research grant income, inferred DoD (AUD Mn)

00.100.58

Australia – interest income (AUD Mn)

0.090.040.02

Total revenue from ordinary activities, all regions (AUD Mn)

0.0200

Share Price & Returns

Reference pointPrice (AUD)Source

8 Oct 2026

0.014

StockAnalysis

25 Sep 2026

0.017

StockAnalysis

5 Aug 2026

0.023

StockAnalysis

31 Jul 2026 (at quarterly release)

0.018

InvestSMART

3 Mar 2026 (at regulatory update)

0.033

InvestSMART

30 Jan 2026

about 0.031–0.04

InvestSMART; Motley Fool

31 Oct 2025

0.023

InvestSMART

52-week high / low

0.049 / 0.016

StockAnalysis

May 2023 (52-wk high then)

0.13

InvestSMART

Nov/Dec 2017 (post-IPO)

about 0.22

Pearler

Share Count (M) and Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Shares on issue at 30 Jun (M)

179.06177.91201.36266.42386.08

Gross equity raised (AUD Mn)

4.7202.031.502.99

Net tangible assets per share (A$ cents)

3.31.71.30.50.5

Dividends per share (A$ cents)

00000

Valuation Snapshot

MultipleValueComment

Market cap

about A$6.1M

—

Enterprise value

about A$4.2M (using 30 Jun 2026 cash of A$1.94M; lower on a pro-forma basis including August proceeds)

Derived

P/E

n/m

Loss-making

EV/EBITDA

n/m

Negative EBITDA

EV/Sales

n/m

Nil revenue

P/B

about 2.9x (on FY2026 equity A$2.09M)

Derived

Fully diluted shares

about 617M (438M + 179M options, all out of the money at 3.4–4.6c)

Derived

Analyst Conclusions

Management guidance (FY2026 AR, operational only).

Consensus growth expectations. None. There is no broker coverage.

Bull case (grounded in the data above).

  1. Regulatory de-risking is close. If OECD 424 and 443 come back clean, roughly 55% of total study duration, per the Mar 2026 update, is behind the company. A Q2 CY2027 APVMA filing would then make Flavocide a dossier-backed novel-MoA active that majors can license, valued from a A$4M enterprise value base.

  2. The synergy patent is a licensing asset. US protection to 2040 for combinations with permethrin and pyrethrin lets incumbents rejuvenate pyrethroid franchises facing resistance. Envu and Clarke are already evaluating formulations.

  3. First revenue and non-dilutive funding are both arriving. A Japan launch with a Sumitomo-group channel in late CY2026 would be the first product revenue. DoD grant income (A$0.58M in FY2026) already offsets about one-third of R&D spending.

Bear case.

  1. Funding treadmill. A$1.94M of year-end cash against A$1.94M of annual burn, a going-concern note, and weak SPP take-up (24%) point to further discounted raises. The 179M options are well out of the money.

  2. Binary toxicology risk and slipping timelines. One study is already delayed (OECD 424). The APVMA target has drifted by about one quarter. Any reproductive or neurotoxicity flag could restrict the label or end the programme.

  3. Nothing binding yet. The Japan deal is a non-binding term sheet. After years of collaborations (BASF, Clarke, Evergreen, Envu, STK), revenue from ordinary activities remained nil in FY2025 and FY2026.

Key catalysts and monitorables (next 12 months).

Concluding analyst verdict.

Bio-Gene Technology is a classic micro-cap "registration option". Its scientific premise is credible, its validation partners are external and serious, and its balance sheet does not match the length of the road ahead. The positives are tangible. The company owns a patented, nature-identical active with a claimed novel mode of action and synergy protection in the US to 2040. Its industrial partners include a Tata-group manufacturer, the former Bayer Environmental Science (Envu), a Sumitomo trading-house channel in Japan, and US DoD, CDC and Purdue scientific validation. FY2026 also showed better cost discipline: the net loss fell to A$2.33M as grant income rose roughly six-fold.

Those positives do not yet translate into a self-funding business. Revenue from ordinary activities is nil. Cash at year end covered only about a year of burn. Auditors and directors flag a material going-concern uncertainty. The share count has risen 2.4x in four years, and the market has priced the equity at about A$6M, below its 52-week low, with an enterprise value of only around A$4M. That valuation implies deep scepticism that Flavocide reaches registration or that partners will pay meaningful licence economics.

The next six to nine months are decisive and well defined. They are: the OECD 424/443 toxicology readouts, which are overdue against September guidance in public disclosures; conversion of the Japan term sheet into a binding supply and licence agreement with a late-2026 launch; and Asian vector-control efficacy data. Clean toxicology together with a signed Japan deal would materially re-rate the risk profile and improve the terms of the inevitable next raise. A toxicology setback or a lapsed Japan deal would likely force highly dilutive funding or a strategic rethink.

Position sizing should treat the September toxicology results, once disclosed, as the gating event, and the APVMA filing in Q2 CY2027 as the first real value inflection.


Sources consulted

  • Bio-Gene Technology Ltd, Appendix 4E and 2026 Annual Report (ASX, 28 Aug 2026)

  • Bio-Gene Technology Ltd, 2025 Annual Report (ASX, 25/26 Aug 2025)

  • Bio-Gene Technology Ltd, Half-Year Reports H1 FY2025 (27 Feb 2025) and H1 FY2026 (24 Feb 2026)

  • ASX announcements: 23 Feb 2023 (H1 FY2023), 26 Feb 2024 (H1 FY2024), 2 Sep 2024 (Rallis), 6 Sep 2024 (Investor Update), 13 Feb 2026 (OECD 424), 27 Apr 2026 (OECD 443), 3 Jun 2026 (Webinar), 24 Jun 2026 (SPP result)

  • InvestSMART announcement summaries (31 Oct 2025; 30 Jan, 24 Feb, 3 Mar, 31 Jul 2026)

  • Kalkine Media (31 Jul 2026); Smallcaps (Mar 2026); Grafa (Feb 2026)

  • StockAnalysis / S&P Global Market Intelligence (income statement, balance sheet, cash flow, quote as of 8 Oct 2026)

  • Market Index BGT company page (listing date, registry, substantial holders as of 20 Aug 2025)

  • Simply Wall St BGT ownership page (Nov 2025); Motley Fool AU BGT page; TipRanks (Alina Barlow substantial holding)

  • Rallis India / Tata Chemicals press release (2 Sep 2024)

  • annualreports.com and Stoxray company profiles; Pearler (IPO date and early price); Musaffa (Shariah screen)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleAppointedPrior rolesEducation

Alex Ding

Non-Executive Chair

NED 12 May 2023; Chair 1 Aug 2023

25+ years corporate lawyer; former partner at two leading Australian firms; M&A and capital markets; named in Best Lawyers in Australia

BComm, LLB (UNSW); LLM (USyd)

Tim Grogan

Managing Director & CEO

28 Aug 2023

CEO, SIRA Pty Ltd (healthier sugar technologies); CEO, Dimerix BioScience (3 pharma partnering deals in 12 months); Starpharma (ASX:SPL), IPO and partnering

BLaw; BSc (Chemistry), University of Melbourne

Peter May

Executive Director – R&D (0.9 FTE)

Director since 29 May 2015

20+ years in crop protection and pest management with Orica and Crop Care (now Nufarm); founded Xavca Pty Ltd (clients incl. Syngenta, Sorex/BASF); CEO then Chair of BioProspect Ltd (ASX:BPO)

BAppSc (Rural Tech)(Hons), UQ; MBA, QUT; GAICD

Andrew Guthrie

Non-Executive Director; Chair, Audit & Risk

26 Apr 2021

32 years at Syngenta and predecessors; Regional Director APAC; led the EAME business; member of Global Crop Protection Leadership team; retired 2019. Also NED of Terragen Holdings (ASX).

BAgSc (Hons); GAICD

Chris Ramsey

Non-Executive Director; Chair, Remuneration & Nomination

12 May 2023

30+ years in agriculture; leadership at Bayer, BASF, Nufarm/Crop Care; NED of North West Phosphate and Zondii; agribusiness consultant

BRurSc (Hons), UNE; GradDip Agribusiness, Monash

Drew Speedy

CFO & Company Secretary (part-time consultant)

1 Feb 2026

Founder and Director, DTS Corporate; 20 years of CFO and company secretary roles

BBus (Acc); CPA; GAICD

Edmond Tern

Former CFO & Company Secretary

Resigned 1 Feb 2026

——

Directors' Remuneration

NameCash salary & feesCash STISuperannuationEquity (STI/LTI)Total FY2026Total FY2025

Tim Grogan

311,003037,3200348,323398,779

Peter May

202,938024,3530227,291245,867

Alex Ding

67,29808,076075,37475,374

Andrew Guthrie

53,36706,404059,77159,771

Chris Ramsey

46,42905,571052,00052,000

Drew Speedy (from 1 Feb 2026)

67,74200067,742—

Edmond Tern (to 1 Feb 2026)

75,42507,071082,496142,941

Total KMP

824,202088,7950912,997974,732

Major Shareholders

HolderSharesOptions% of 438.06M shares

Alex Ding (incl. Vana Belle Pty Ltd)

34,122,08121,739,1307.8

Peter May

2,259,597317,3920.5

Andrew Guthrie

684,784317,3920.2

Drew Speedy

600,000300,0000.1

Tim Grogan

476,916317,3920.1

Chris Ramsey

319,000100,0000.1

Total directors and CFO

38,462,378

—

about 8.8

Major Shareholders (Annual)

HolderShares (Aug 2025)% thenNote

Dr Choon Huat Lee

32,791,24510.7

Bought in the May 2025 placement

Vana Belle Pty Ltd (Ding-associated)

21,739,130+

~11.2 (Simply Wall St, Nov 2025)

Since increased to 34.1M total per AR

Mark Chang

21,109,1746.9—

Alina Barlow

18,995,8596.2

Became substantial at 7.59% (12 May 2025)

Citicorp Nominees Pty Ltd

15,166,4915.0

Custodian

T & L Ainsworth Investments

6,683,1852.2—

Maclee Pty Ltd

3,650,0001.2—

Competitive Landscape

Key Competitors

CompetitorSegment overlapPositioning vs Bio-Gene

Syngenta Group

Crop protection, public health (vector control)

Global discovery engine with novel-MoA insecticides; potential licensee

Bayer Crop Science

Crop protection

Large pipeline; former parent of Envu

BASF Agricultural Solutions

Crop, public health, grain storage

Former Flavocide grain collaborator

Corteva Agriscience

Crop protection, biologicals

Spinosyn and natural-derived insecticides (direct analogue to "nature-derived" claim)

FMC Corporation

Crop protection

Diamide franchise; biologicals

Sumitomo Chemical

Household and public-health pyrethroids, vector control

Dominant in household insecticides in Japan; Sumitomo Corporation (separate trading house) is a Bio-Gene partner

Envu

Professional pest and vector control

Current partner; also sells competing actives

Nufarm (ASX: NUF)

Crop protection (off-patent)

Australian peer; generic pyrethroids

Vestaron (private, US)

Peptide bio-insecticides, novel MoA

Closest "novel MoA biological" analogue

Certis Biologicals / Mitsui

Biopesticides

Commercial botanical/microbial portfolio

Marrone Bio (now Bioceres)

Biopesticides

Commercial biologicals

Terragen Holdings (ASX: TGH)

Ag biologicals (ASX micro-cap)

Shares director Guthrie

Clarke

Mosquito control

Partner and channel

Peer Comparison FY2026

MetricBio-Gene (FY2026)FMC (2024)Nufarm (FY2024)Corteva (2024)

Revenue

A$0

~US$4.2bn

~A$3.3bn

~US$16.9bn

Revenue growth

n/m

Negative (destocking)

Negative

~Flat

Operating margin

n/m (loss A$2.36M)

Positive, high single/low double digit

Low single digit

Positive, low double digit

R&D intensity

n/m (R&D A$1.77M)

~7% of sales

Low (~2%)

~8% of sales

Recent Developments

--

Company Snapshot

1

Employees

1995

Founded

Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • A novel mode of action is claimed for flavesone, validated against resistant pest populations (FY2026 AR).
  • A US patent on flavesone plus permethrin/pyrethrin synergy runs to 2040, with equivalents in AU, JP, NZ and 22 ARIPO states (FY2026 AR).
  • Non-dilutive funding: about A$3.0M in US DoD grants. Grant income was A$0.58M in FY2026 and lifted other income to A$1.08M (AR Note 3a).
  • Scalable manufacturing has been shown: Rallis pilot batches produced several hundred kg at consistent quality (Sep 2024).
  • Qcide holds an unrestricted OMRI listing as 100% natural and non-synthetic (Dec 2025).
  • The board has deep agrochemical networks: Guthrie (Syngenta EAME head), Ramsey (Bayer/BASF/Nufarm) and May (Orica/Crop Care).
  • There is no debt, and liabilities are only A$0.52M (FY2026 AR).

Weaknesses

  • Revenue from ordinary activities was nil in FY2025 and FY2026 (Appendix 4E).
  • Going-concern material uncertainty is disclosed in the FY2026 AR and H1 FY2026 accounts.
  • Cash was A$1.94M against FY2026 operating burn of A$1.94M, about 12 months of runway.
  • Heavy dilution: shares rose from 179M (FY2022) to 438M (Aug 2026), with 179M options outstanding.
  • Accumulated losses reached A$24.2M with no registered product after about 30 years since incorporation.
  • Execution slippage: the OECD 424 preliminary report moved from May to Sep 2026, and the APVMA target from "March 2027" to "Q2 CY2027".
  • There is no board gender diversity and the finance function is part-time (CFO on consulting contract).

Opportunities

  • A first commercial Qcide launch in Japan with Sumitomo/Nakashima is targeted for late CY2026.
  • Licensing synergy combinations could extend the life of incumbents' pyrethroids (US patent to 2040).
  • Asian dengue-vector programmes: WHO-guideline testing should report Q4 CY2026.
  • Lyme-disease tick control in the US (>90% nymph mortality, Purdue).
  • Defence procurement if the wearable emanator succeeds (DoD DWFP).
  • Organic agriculture via STK and the OMRI listing.

Threats

  • Adverse findings in OECD 443 or 424 could delay or derail Flavocide registration (AR risk "Laboratory and Field Trials").
  • Inability to raise capital on acceptable terms: the 2026 SPP drew only A$119.5k of A$500k (24 Jun 2026).
  • The Japan deal is non-binding and could fail to convert.
  • Competitors may deliver more effective novel modes of action first (AR "Out-licencing" risk).
  • Single-site Qcide plantation exposed to weather, pests and yield variability (AR "Manufacturing" risk).
  • R&D tax incentive clawback risk under AusIndustry review (AR Note 16).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
12 May 2025Placement tranche 1 (50.34M shares at 2.3c); Alina Barlow becomes substantial (7.59%); Dr Choon Huat Lee buys about 21.7M sharesNew anchor private investors
May–Jun 2025SPP raises A$338,499 (14.72M shares)Retail support
18 Jul 2025Tranche 2: 41.96M shares (A$965,121); 110.07M options issued (3.4c/2028 and 4.6c/2030); LSP tranches 1a/2a/3a cancelled (3.32M shares)Completes A$2.46M raise
21 Jul 2025Directors buy in the placement after approval: Vana Belle (Ding) A$500k; Grogan, May, Guthrie A$5k eachInsider alignment
Jul 202514th Qcide harvestSupply validation
20 Aug 2025Substantial holder registry: Lee 10.7%, Chang 6.9%, Barlow 6.2%, Citicorp 5.0%Concentrated register
25–26 Aug 2025FY2025 Annual Report: loss A$2.58M (+7.3%), cash A$1.14MFunding strain
23 Sep 2025Purdue reports >90% tick nymph mortality with Flavocide at the Lyme conferenceNew acaricide use
31 Oct 2025Q1 FY2026 quarterly: strategic pipeline review; about 0.98 quarters of fundingLiquidity flag
Nov 2025A$519,502 R&D tax incentive refundNon-dilutive cash
Nov 2025AGM: remuneration report passes with >98.99%Governance support
Dec 2025Qcide OMRI listing (USDA NOP)US organic market access
30 Jan 2026Q2 FY2026 quarterly; DoD programmes (A$3.0M) progressingUpdate
1 Feb 2026CFO/CoSec change: Speedy replaces TernFinance leadership change
13 Feb 2026OECD 424 acute neurotoxicity study underway; preliminary report guided for May 2026Regulatory critical path
Feb 202615th Qcide harvestSupply
24 Feb 2026H1 FY2026: other income A$466k (+516%), loss A$1.40M (−4.4%); going-concern uncertaintyInterim results
3 Mar 2026Flavocide regulatory roadmap: APVMA submission targeted March 2027; studies equal about 55% of total study durationTimeline set; stock falls about 48% from release price over following months
Mar 2026Non-binding Qcide term sheet with Sumitomo and Nakashima (Japan)First commercial pathway
9 Apr 2026Auditor changes to Horizon Nexus (ASIC consent)Governance
27 Apr 2026OECD 443 reproductive study underway (preliminary Sep 2026, final Nov 2026); Q3 quarterlyRegulatory
May 2026OECD 424 preliminary report delayed by a CRO software error; filing timing said to be unaffectedExecution risk
May 2026Asia mosquito vector-control evaluation launchedMarket expansion
22 May 2026Trading halt pending capital raise—
26 May 2026A$3.275M placement and A$500k-underwritten SPP announced at 2.5cFunding
2 Jun 202676.24M placement shares issued (A$1.906M)Funding
4 Jun 2026Investor webinar (CEO presentation)IR
Jun/Jul 2026US patent for flavesone + permethrin/pyrethrin synergy (to 2040)IP moat
24 Jun 2026SPP result: only A$119,500 applied; A$380,500 shortfall to the underwriterWeak retail demand
Jul 2026Peter May receives Envu Australian Individual Excellence Professional Pest Management Award 2026Industry standing
31 Jul 2026Q4 FY2026 quarterly: cash A$1.94MUpdate
5 Aug 2026EGM approves related-party placement, SPP shortfall and options (>96%)Funding completed
10 Aug 202652M shares and 69.2M options (3.5c, Oct 2027) issuedDilution
28 Aug 2026FY2026 Annual Report: loss A$2.33M (−9.8%); APVMA target restated as Q2 CY2027Slight timeline slippage
Sep 2026Preliminary OECD 424 and 443 reports due per company guidance. No public result announcement located in this research.Key monitorable
8 Oct 2026Shares at A$0.014, below the 52-week low of A$0.016Market scepticism

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (%): Segment share of total revenue held from 100% in FY2024 to 100% in FY2026.
Bio-Gene Technology Limited — Revenue by Segment (%)
Series (%)FY2024FY2025FY2026
Segment share of total revenue100100100

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.